BeiGene, Ltd. Market Cap ($32.38 Billion)
Market Cap & Net Worth: BeiGene, Ltd. (ONC)
BeiGene, Ltd. market cap. BeiGene, Ltd. (NASDAQ:ONC) has a market capitalization of $32.38 Billion ($32.38 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #834 globally and #377 in its home market, demonstrating a -3.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BeiGene, Ltd.'s stock price $371.56 by its total outstanding shares 94900812 (94.90 Million).
BeiGene, Ltd. Market Cap History (2025–2026)
BeiGene, Ltd. market cap history from 2025 to 2026. Data shows growth from $28.83 Billion to $35.26 Billion (48.54% CAGR). Check BeiGene, Ltd. (ONC) share price today for real-time trading data and today's change.
Index Memberships
BeiGene, Ltd. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 1.23% | #12 of 976 |
Weight: BeiGene, Ltd.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BeiGene, Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BeiGene, Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash efficiency ratio of BeiGene, Ltd. for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
5.40x
BeiGene, Ltd.'s market cap is 5.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
100.48x
BeiGene, Ltd.'s market cap is 100.48 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $28.83 Billion | $5.34 Billion | $286.93 Million | 5.40x | 100.48x |
Competitor Companies of ONC by Market Capitalization
Companies near BeiGene, Ltd. in the global market cap rankings as of October 31, 2026. See BeiGene, Ltd. net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to BeiGene, Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of BeiGene, Ltd. (2025–2026)
Market capitalization of BeiGene, Ltd. from 2025 to today. Between 2025 and today, BeiGene, Ltd.'s market cap moved from $28.83 Billion to $ 35.26 Billion, with a yearly change of 48.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $35.26 Billion | +22.30% |
| 2025 | $28.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of BeiGene, Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.38 Billion USD |
| MoneyControl | $32.38 Billion USD |
| MarketWatch | $32.38 Billion USD |
| marketcap.company | $32.38 Billion USD |
| Reuters | $32.38 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more